Pre-market Movers For Oct 28 (BIIB, MRK, MOS, BKW, DNDN, CLVS, SOHU, CYOU, SNTA)

(RTTNews) - Gainers:

Biogen Idec Inc. (BIIB) is gaining over 2 percent to $258.25. The company's third quarter profit improved from the previous year period. Total revenues improved 32 percent and came in above the consensus estimate. The company also increased its full year 2013 financial guidance.

Mosaic Co. (MOS) is up nearly 2 percent to $46.77. The company agreed to acquire the phosphate business of CF Industries Inc. (CF) for $1.2 billion in cash plus $200 million to fund CF Industries' asset retirement obligation escrow.

Burger King Worldwide, Inc. (BKW) is gaining 3 percent to $20.32 after its third quarter results topped Wall Street view.

Dendreon Corp. (DNDN) is surging 22 percent to $3.10 amidst reports that the company is seeking suitable buyers.

Clovis Oncology, Inc. (CLVS) is up 14 percent to $3.10. The company announced that CO-1686 continues to demonstrate promising clinical activity and safety in updated phase I study results.

Decliners:

Merck & Co. Inc. (MRK) is falling over 1 percent to $45.82. The company's third quarter earnings declined from the previous year period. Worldwide sales fell 4 percent reflecting the unfavorable impact of patent expiries and a 2 percent negative impact from foreign exchange. The company also narrowed its full-year earnings guidance. JANUVIA sales fell 5 percent, while SINGULAIR sales plunged 53 percent, due to patent expiry.

Sohu.com Inc. (SOHU) is declining 9 percent to $73.98 and Changyou.com Ltd. (CYOU) is falling 17 percent to $29.65 following the release of their quarterly results.

Synta Pharmaceuticals Corp. (SNTA) is declining 20 percent to $5.10. The company announced presentation of results from the GALAXY-1 trial designed to identify the patients with advanced non-small cell lung adenocarcinoma most likely to benefit from second-line treatment with its lead drug candidate, the Hsp90 inhibitor ganetespib, in combination with docetaxel versus docetaxel alone.

Trading halt:

Trading in shares of Anacor Pharmaceuticals, Inc. (ANAC) was halted. The company announces settlement agreement with Valeant Pharmaceuticals (VRX, VRX.TO). Valeant to pay Anacor $142.5 million to settle disputes related to Dow Pharmaceutical Sciences and Medicis Pharmaceutical Corp.